Pharma Exclusives Pressreleases
Thermo Fisher Scientific Launches New Spectral Flow Cytometer Offering Increased Speed, Versatility and Reliability to Labs
Thursday, May 29, 2025Thermo Fisher Scientific Inc the world leader in serving science today launched the spectralenabled Invitrogen Attune Xenith Flow Cytometer allowing immunology and immunooncology researchers to automate and streamline workflows
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics
Wednesday, May 28, 2025Eli Lilly and Company and SiteOne Therapeutics Inc a private biotechnology company developing small molecule inhibitors of sodium channels to treat pain and other neuronal hyperexcitability disorders today announced a definitive agreement for Lilly t...
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
Wednesday, May 28, 2025Teva Pharmaceutical Industries Ltdtoday announced that the US Food and Drug Administration FDA granted Fast Track designation for investigational TEV an antiIL antibody for the treatment of people with celiac disease
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
Wednesday, May 28, 2025Bristol Myers Squibb today announced that the European Commission EC has approved a new Opdivo nivolumab formulation associated with a new route of administration subcutaneous use SC a new pharmaceutical
Biogen and City Therapeutics Announce Strategic Research Collaboration to Develop Select Novel RNAi-based Therapies
Tuesday, May 27, 2025Biogen Incand City Therapeutics Inc a privately held biopharmaceutical company leading the future of RNA interference RNAibased medicine today announced a strategic collaboration to develop select novel RNAi therapies
Pfizer Enters into Exclusive Licensing Agreement with 3SBio
Tuesday, May 20, 2025Pfizer Inc today announced it has entered into an exclusive global exChina licensing agreement with SBio Inc HK a leading Chinese biopharmaceutical company for the development manufacturing and commercialization of SSGJ
Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for Airsupra as standard of care for as-needed rescue treatment in asthma
Tuesday, May 20, 2025Positive full results from the BATURA Phase IIIb trial showed AstraZenecas antiinflammatory reliever rescue therapy Airsupra albuterolbudesonide demonstrated statistically significant and clinically meaningful improvements in
Cybin Applauds FDA Commissioner Dr. Martin Makary’s Call to Accelerate and Prioritize Research on Psychedelic Therapeutics
Tuesday, May 20, 2025Cybin Inc a clinicalstage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative nextgeneration treatment options applauds recent comments made by Dr Martin Makary
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Monday, May 19, 2025The first patient has been dosed in the IDeateEsophageal Phase trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan IDXd versus investigators choice of chemotherapy in patients with unresectable
Sanofi to invest at least $20 billion in the US through 2030, growing investments in science and expanding domestic manufacturing
Thursday, May 15, 2025Sanofi today announces its intention to invest at least billion in the United States through The expected investment includes a significant increase in research and development spending and the allocation of billions of dollars to US manufacturing
